Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
IQV | US
1.60
1.00%
Healthcare
Diagnostics & Research
30/06/2024
24/04/2026
162.28
161.33
163.93
160.20
IQVIA Holdings Inc. engages in the provision of advanced analytics technology solutions and clinical research services to the life sciences industry in the Americas Europe Africa and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products prescribing trends medical treatment and promotional activity across various channels including retail hospital and mail order; and measurement of sales or prescribing activity at the regional zip code and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials as well as central laboratory genomic bioanalytical ADME discovery and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services and scientific strategy and medical affairs services. It serves pharmaceutical biotechnology device and diagnostic and consumer health companies. The company was formerly known as Quintiles IMS Holdings Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was incorporated in 2016 and is headquartered in Durham North Carolina.
View LessLargecap (10B - 200B USD)
Price Below SMA10D
High Short-term Volatility
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
50.9%1 month
40.7%3 months
50.1%6 months
39.1%30.78
18.90
6.43
2.00
0.51
16.47
3.62
1.17
2.78B
29.58B
29.58B
-
14.37
23.90
2.30
22.84
2.39
1.94
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
24.66
Range1M
24.66
Range3M
87.84
Rel. volume
0.75
Price X volume
143.04M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. | GEHC | Health Information Services | 68.83 | 31.43B | -1.52% | 26.40 | 123.86% |
| Mettler-Toledo International Inc | MTD | Diagnostics & Research | 1282.45 | 27.21B | 1.43% | 37.74 | -1347.12% |
| Veeva Systems Inc | VEEV | Health Information Services | 161.13 | 26.09B | 3.19% | 59.18 | 1.04% |
| Koninklijke Philips N.V | PHG | Diagnostics & Research | 27.47 | 25.60B | -0.58% | n/a | 69.56% |
| Natera Inc | NTRA | Diagnostics & Research | 203.75 | 25.20B | 1.30% | n/a | 52.31% |
| DexCom Inc | DXCM | Diagnostics & Research | 61.57 | 24.67B | -1.80% | 44.96 | 106.57% |
| Laboratory Corporation of America Holdings | LH | Diagnostics & Research | 263.8 | 22.15B | -0.42% | 40.18 | 74.63% |
| Quest Diagnostics Incorporated | DGX | Diagnostics & Research | 196.27 | 21.85B | -1.63% | 20.22 | 76.89% |
| Illumina Inc | ILMN | Diagnostics & Research | 127.88 | 20.37B | 1.95% | n/a | 203.41% |
| Waters Corporation | WAT | Diagnostics & Research | 309.87 | 18.39B | -0.43% | 34.84 | 147.93% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| PPL Corporation | PPL | Building Products & Equipment | 38.75 | 28.59B | 0.54% | 28.90 | 114.80% |
| Twenty-First Century Fox Inc | FOXA | Media - Diversified | 62.85 | 27.58B | -2.60% | 13.57 | 76.09% |
| Twenty-First Century Fox Inc | FOX | Media - Diversified | 56.17 | 26.86B | -2.72% | 12.45 | 76.09% |
| Avery Dennison Corporation | AVY | Building Products & Equipment | 165.5 | 13.33B | -1.15% | 27.93 | 140.74% |
| Dolby Laboratories Inc | DLB | Media - Diversified | 64.08 | 6.11B | 1.78% | 34.32 | 0.00% |
| FBIN | FBIN | Building Products & Equipment | 41.54 | 5.16B | 0.34% | 25.57 | 130.24% |
| Thor Industries Inc | THO | Recreational Vehicles | 79 | 4.18B | 0.24% | 23.44 | 27.88% |
| Cinemark Holdings Inc | CNK | Media - Diversified | 28.48 | 3.49B | -0.42% | 27.93 | 934.91% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 27.25 | 3.39B | 0.96% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 60.04 | 3.35B | 1.06% | 14.48 | 170.51% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 16.47 | 12.67 | Expensive |
| Ent. to Revenue | 3.62 | 44.00 | Cheaper |
| PE Ratio | 30.78 | 40.09 | Cheaper |
| Price to Book | 6.43 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 50.12 | 59.59 | Par |
| Debt to Equity | 2.00 | -14.36 | Expensive |
| Debt to Assets | 0.51 | 0.34 | Expensive |
| Market Cap | 29.58B | 13.71B | Market Leader |